Diagnos Inc. (TSX Venture: ADK) (OTCQB: DGNOF) (FWB: 4D4A), a company specializing in early detection of critical health issues using Artificial Intelligence-based technology, has announced an engagement with Investor Brand Network (“IBN”) to provide corporate communication and awareness solutions. The one-year agreement, effective January 10, 2026, involves monthly compensation of US$6,400 payable in advance from the Corporation’s funds. IBN will assist Diagnos in refining and strengthening its market awareness profile with the objective of maximizing shareholder value. The engagement remains subject to acceptance by the TSX Venture Exchange.
This partnership is significant as it represents a strategic move by Diagnos to enhance its visibility within the investment community. By leveraging IBN’s specialized communications platform, Diagnos aims to efficiently reach target markets and demographics. IBN, which is part of the Dynamic Brand Portfolio, offers services including advanced wire-grade press release syndication, article and editorial syndication to over 5,000 outlets, enhanced press release optimization, and social media distribution to millions of followers. The engagement is structured with IBN acting at arm’s length, and neither IBN nor its principals hold any direct or indirect interest in Diagnos’s securities.
The implications of this announcement extend beyond mere corporate communications. For a publicly traded company like Diagnos, which is dedicated to early detection of critical eye-related health problems through AI technology, increased market awareness can directly impact shareholder value and investor confidence. Enhanced visibility through platforms like InvestorWire can facilitate broader recognition among investors, influencers, and the general public, potentially leading to improved capital market engagement. Additional information about Diagnos is available at www.diagnos.com and www.sedarplus.com.
This move aligns with Diagnos’s mission to leverage Artificial Intelligence to provide healthcare clinicians with more information for enhanced diagnostic accuracy, streamlined workflows, and improved patient outcomes globally. By cutting through the information overload in today’s market, IBN’s services aim to bring Diagnos unparalleled recognition and brand awareness. The financial commitment of US$6,400 per month reflects the company’s investment in strategic communications as a component of its corporate strategy. The latest news and updates relating to DGNOF are available in the company’s newsroom at https://ibn.fm/DGNOF.
